MarketInOut Stock Screener Log In | Sign Up
 

Halozyme Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/06/2026 16:00
Halozyme Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,886.39 mln
Float117 mln
Earnings Date08/06/2026

EPS

2.85
Stretched

P / E

30.09
Overvalued

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-1.9
Caution advised

1-Year Forecast

86.89
Fairly priced

Relative Strength

79 / 100
Strongly outperforming

Business Description

Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California, that develops a proprietary enzyme technology enabling drugs to be delivered by injection just beneath the skin rather than through a vein. This approach, built around its patented rHuPH20 enzyme, is licensed to many of the world's leading pharmaceutical companies and supports a wide range of treatments for conditions including cancer, multiple sclerosis, and autoimmune diseases. Founded in 1998, the company operates across the United States and several international markets, generating revenue primarily through its partnerships and licensing agreements rather than direct drug sales.

Key Fundamentals

EPS2.85
P/E30.09
ROE110
RPS12.28
ROIC33.76
ROA14.95
Interest Cover44.25
EBITDA, mln624
EV / EBITDA18.42
EV / EBIT21.99
Revenue, mln1,508
EV / Revenue7.62

Financial Strength

Altman Z-Score3.98
Piotroski F-Score 5 / 9
Beneish M-Score-1.9
Price to Intrinsic Value2.14
Price to Lynch Fair Value0.92
1-Year Target Price86.89
Shiller PE Ratio60.08
Short Ratio6.68
Short % of Float14.50

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.95% 67 / 100   
1 Month 6.71% 83 / 100   
2 Months 36% 93 / 100   
6 Months 10.05% 69 / 100   
1 Year 41.03% 82 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us